Navigation Links
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
Date:11/10/2008

Examination (MMSE), and a significant inverse relationship between increased total and LDL cholesterol and learning and memory. Elevated cholesterol levels are thought to increase the production and accumulation of the putative AD neurotoxin, amyloid-beta (A-beta). The A-beta peptide is produced by aberrant cleavage of a larger precursor protein resulting in two lengths, either 42 or 40 amino acids long.

"Stemming from RVX-208's effects on ApoA-I, Prebeta-HDL production and the facilitation of reverse cholesterol transport, we hypothesized that RVX-208 might increase circulating A-beta40 levels through its effects on functional HDL, which can act as a sponge to draw A-beta40 from the brain to the circulation, for enhanced clearance from the body," stated Dr. Sparks. "Although it was a pilot study, with minimal subjects, we were pleased to find a positive signal and look forward to performing further research on RVX-208 in this critical area of unmet medical need," Dr. Sparks added.

"We are pleased and cautious about these early results," stated Kenneth Lebioda, Senior Vice President of Business and Corporate Development of Resverlogix. "This data provides important evidence solidifying our strategy to continue research efforts in this important disease area. We have always maintained a strategic life cycle management strategy that ensures the pursuit of important research in areas of critical unmet need. Our progress in Alzheimer's disease research illustrates our commitment to build a broad portfolio of opportunities in areas of unmet need for our lead drug and our NexVas(TM) platform technology. We look forward to continue our research collaboration with Dr. Sparks in this important medical area."

About RVX-208

RVX-208, a first in class novel small molecule therapeutic that facilitates endogenous Apolipoprotein A-I (ApoA-I) production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis and v
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. International Steering Committee for RVX-208 IVUS Trial Formed
2. Phase 1b/2a Program Commences for RVX-208
3. Industry Leaders Select Resverlogixs RVX-208
4. Dosing for RVX-208 Phase 1a Clinical Study Completed
5. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
6. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
7. deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
8. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
9. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
10. New Study Shares Best Practices in Biopharma Public Relations
11. Study From the University of Texas M.D. Anderson Cancer Center Demonstrates That AHCC(R) is Safe in Combination With Most Chemotherapeutic Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015  Pfenex Inc. ... in the development of biosimilar therapeutics including high ... the closing of its previously announced underwritten public ... at a public offering price of $15.50 per ... the underwriters of their option to purchase up ...
(Date:4/30/2015)... 2015 Available in select spas ... , Fleur’s introduces CC CRÈME ... benefits of makeup, skin care and solar protection ... is designed with specific complexion-correcting pigments to instantly ... and a healthy glow. Far more than a ...
(Date:4/30/2015)... 30, 2015 Sterlitech is proud ... the PX, PY, and PZ Polyacrylonotrile (PAN) ... disks. Designed to be ideal for oil ... can fill critical process requirements where the presence ... , “New regulations on industrial wastewater discharge and ...
(Date:4/29/2015)... April 29, 2015   Doximity , the leading ... US doctors as members, announced a new, instant method ... Using Doximity." With one click, all US physicians can ... vitae (CV) for an open job opportunity, and a ... Eighty seven percent of physicians are open to ...
Breaking Biology Technology:Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 2Fleur’s Introduces CC CRÈME Perfect Skin Solution 3Sterlitech Offers New Ultrafiltration Membranes 2Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2
... Imaging Services to Unprecedented Number of ... Claustrophobic, Elderly and Bariatric Patients, MALVERN, Pa., Feb. ... become the first facility in the United,States to install ... Solutions (http://www.usa.siemens.com/healthcare ) -- the,MAGNETOM(R) Verio. Combining 3 ...
... Feb. 4 Cell,Genesys, Inc. (Nasdaq: CEGE ) ... executive officer of Cell Genesys, will present a,company update ... York, New,York, on Monday, February 11, 2008 at 11:00 ... presentation will be accessible through the,Investor Relations section of ...
... Centocor, Inc. announced today,that the Biologics License ... for review by the U.S. Food and Drug ... chronic moderate to severe plaque,psoriasis. Ustekinumab is a ... action that targets the cytokines interleukin-12 (IL-12) and,interleukin-23 ...
Cached Biology Technology:Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 2Johns Hopkins Bayview at Forefront of Expanding Access to MRI With First Install of Siemens New MAGNETOM Verio 3Cell Genesys to Present at the BIO CEO and Investor Conference 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 2Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA 3
(Date:3/23/2015)... 23, 2015 SoundView Technology Group issues a new ... NXTD ) Wocket smart wallet. SoundView was one of the selected ... experience with the Wocket in multiple scenarios and outlets. ... and other retailers, making both debit and credit card payments.  ... says, "If the company meets their plans in 2015, it ...
(Date:3/23/2015)... 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... CNBC television starting March 30 th . ... New York markets. ... excited about our new ad campaign following the recent initial ...
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... received a $3.3 million contract from the U.S. Defense Advanced ... be so soft and squishy that they will be able ... morph back into something 10 times larger, and ultimately biodegrade. ... conduct dangerous or difficult operations are clear, and the U.S. ...
... essential hypertension also develop diabetes and other complications in ... discovered a common molecular mechanism in a strain of ... in mammals. , The bioengineering researchers at UC San ... drug developed for unrelated purposes in humans was effective ...
... Crohn,s disease researchers has combined data from three ... associated with the inflammatory bowel disorder, bringing the ... Several of these are involved with the immune ... that disruptions in a process called autophagy may ...
Cached Biology News:Tufts to develop morphing 'chemical robots' 2Tufts to develop morphing 'chemical robots' 3A single mechanism for hypertension, insulin resistance and immune suppression 2A single mechanism for hypertension, insulin resistance and immune suppression 3A single mechanism for hypertension, insulin resistance and immune suppression 4International team identifies 21 new genetic risk factors for Crohn's disease 2
... of use and flexibility of the BDTM LSR, the ... LSR II. The BD LSR II has performance, ... analyzer. Free up your high-performance cell sorter by ... the BD LSR II. The BD LSR II can ...
... System is a full featured, two laser, six ... Flow Cytometer, CFlow Software, and a PC for ... provides all the capabilities of the best selling ... The C6 Flow Cytometer System has six detectors ...
...
Fingerprinting II Basic software is used for analyzing fingerprint sample types (electrophoretic gels, HPLC and other chromatographic patterns, spectrophotometric and densitometric curves)....
Biology Products: